Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLAR 4 trial of selonsertib in compensated cirrhosis due to NASH
MOH_2017-08-31_000334Phase 3Recruiting
- Sponsor
- Gilead Sciences
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of selonsertib in metabolic dysfunction-associated steatohepatitis (MASH) and Cirrhosis (3 arms), sponsored by Gilead Sciences. Started Aug 2017; status: recruiting.
02
Drugs
selonsertib
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on MOH_2017-08-31_000334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-08-31_000334.